We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

000963:SSEHuadong Medicine Co., Ltd Analysis

Data as of 2026-09-05 - not real-time

CN¥27.37

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Huadong Medicine Co., Ltd trades at ¥27.37, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. Over a rolling month the price has lost 4.2%. With RSI at 42.0 the momentum picture is neutral, alongside a bearish MACD signal. Watch ¥26.93 as support and ¥30.67 as the nearer resistance level.
Valuation screens as undervalued: a P/E of 13.8 sits below the sector average of 30.6. The average analyst target implies 52.0% above today's level. The 3.39% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 5 — moderate. With 30-day volatility of 32.7%, a beta of 0.06 and a maximum drawdown of 39.7%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
This one splits by horizon — sell in the near term, buy further out, at 4/10 long-term conviction.

Top Market Events

Huadong Medicine Co Ltd has remained active with business and product updates, drawing attention toHuadong Medicine Co Ltd has expanded its oncology and aesthetics pipeline through new licensing agread-hoc-news4monHuadong Medicine Co Ltd stock CNE1000013Y0 : Why does its pharma innovation strategy matter more now for...

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 34.04
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • P/E of 13.8 versus sector average of 30.6
  • Trading below the 200-day average of 34.04

Long Term

> 3 years
Positive
Model confidence: 4/10

Key Factors

  • P/E of 13.8 versus sector average of 30.6
  • Analyst targets imply +52.0% versus the current price
  • Revenue contracting at -0.5%

Key Metrics & Analysis

Financial Health

Revenue Growth-0.50%
Profit Margin7.86%
P/E Ratio13.8
ROE13.82%
ROA6.35%
Debt/Equity8.63
P/B Ratio1.9
Op. Cash FlowCN¥4.3B
Free Cash FlowCN¥2.6B
Industry P/E30.6

Technical Analysis

TrendBearish
RSI42.0
SupportCN¥26.93
ResistanceCN¥30.67
MA 20CN¥28.34
MA 50CN¥29.03
MA 200CN¥34.04
MACDBearish
VolumeDecreasing
Fear & Greed Index95.48

Valuation

Fair ValueCN¥20.64
Target PriceCN¥41.59
Upside/Downside51.96%
GradeUndervalued
TypeValue
Dividend Yield3.39%

Risk Assessment

Beta0.06
Volatility32.71%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.